De-risk & accelerate the drug development process for gene therapy

In today’s challenging financial environment, it is more important than ever to get key biotech business decisions right first time. One of the most important and topical of these is the choice of CDMO partner. Dr Kim Watanabe, General Manager and Site Head for Patheon Translational Services, a part of the Thermo Fisher Scientific pharma services contract development and manufacturing organizational arm, joins BioInsights to share her advice and insights into optimizing outsourcing strategy.

Chapters

• 1:04 Key high level trends impacting gene therapy biotech decision-making around outsourcing
• 3:54 When should small biotechs engage with CDMOs?
• 5:24 What can CDMOs do to provide bits of support to biotech until they are ready?
• 7:15 Solve the challenges of doing business today and addressing concerns of the future?
• 8:50 What should be considered when choosing a CDMO partner?